OliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration
News (ZH) - LGC will produce active pharmaceutical ingredients for preclinical and clinical study of OLX301D programme